tetano
Editor, Senior Moderator
Sci Rep
. 2023 Sep 8;13(1):14789.
doi: 10.1038/s41598-023-41763-5. Efficient symptomatic treatment and viral load reduction for children with influenza virus infection by nasal-spraying Bacillus spore probiotics
Tu Thanh Tran[SUP] #[/SUP][SUP] 1 [/SUP], Thuy Thi Bich Phung[SUP] #[/SUP][SUP] 2 [/SUP], Dien Minh Tran[SUP] #[/SUP][SUP] 3 [/SUP], Huyen Thi Bui[SUP] #[/SUP][SUP] 4 5 [/SUP], Phuc Thanh Thi Nguyen[SUP] 1 [/SUP], Tam Thi Vu[SUP] 1 [/SUP], Nga Thi Phuong Ngo[SUP] 1 [/SUP], Mai Thi Nguyen[SUP] 1 [/SUP], Anh Hoa Nguyen[SUP] 6 7 [/SUP], Anh Thi Van Nguyen[SUP] 8 [/SUP]
Affiliations
Influenza virus is a main cause of acute respiratory tract infections (ARTIs) in children. This is the first double-blind, randomized, and controlled clinical trial examining the efficacy of nasal-spraying probiotic LiveSpo Navax, which contains 5 billion of Bacillus subtilis and B. clausii spores in 5 mL, in supporting treatment of influenza viral infection in pediatric patients. We found that the nasal-spraying Bacillus spores significantly shortened the recovery period and overall treatment by 2 days and increased treatment effectiveness by 58% in resolving all ARTIs' symptoms. At day 2, the concentrations of influenza virus and co-infected bacteria were reduced by 417 and 1152 folds. Additionally, the levels of pro-inflammatory cytokines IL-8, TNF-α, and IL-6 in nasopharyngeal samples were reduced by 1.1, 3.7, and 53.9 folds, respectively. Compared to the standard control group, treatment regimen with LiveSpo Navax demonstrated significantly greater effectiveness, resulting in 26-fold reduction in viral load, 65-fold reduction in bacterial concentration, and 1.1-9.5-fold decrease in cytokine levels. Overall, nasal-spraying Bacillus spores can support the symptomatic treatment of influenza virus-induced ARTIs quickly, efficiently and could be used as a cost-effective supportive treatment for respiratory viral infection in general.Clinical trial registration no: NCT05378022 on 17/05/2022.
. 2023 Sep 8;13(1):14789.
doi: 10.1038/s41598-023-41763-5. Efficient symptomatic treatment and viral load reduction for children with influenza virus infection by nasal-spraying Bacillus spore probiotics
Tu Thanh Tran[SUP] #[/SUP][SUP] 1 [/SUP], Thuy Thi Bich Phung[SUP] #[/SUP][SUP] 2 [/SUP], Dien Minh Tran[SUP] #[/SUP][SUP] 3 [/SUP], Huyen Thi Bui[SUP] #[/SUP][SUP] 4 5 [/SUP], Phuc Thanh Thi Nguyen[SUP] 1 [/SUP], Tam Thi Vu[SUP] 1 [/SUP], Nga Thi Phuong Ngo[SUP] 1 [/SUP], Mai Thi Nguyen[SUP] 1 [/SUP], Anh Hoa Nguyen[SUP] 6 7 [/SUP], Anh Thi Van Nguyen[SUP] 8 [/SUP]
Affiliations
- PMID: 37684332
- DOI: 10.1038/s41598-023-41763-5
Influenza virus is a main cause of acute respiratory tract infections (ARTIs) in children. This is the first double-blind, randomized, and controlled clinical trial examining the efficacy of nasal-spraying probiotic LiveSpo Navax, which contains 5 billion of Bacillus subtilis and B. clausii spores in 5 mL, in supporting treatment of influenza viral infection in pediatric patients. We found that the nasal-spraying Bacillus spores significantly shortened the recovery period and overall treatment by 2 days and increased treatment effectiveness by 58% in resolving all ARTIs' symptoms. At day 2, the concentrations of influenza virus and co-infected bacteria were reduced by 417 and 1152 folds. Additionally, the levels of pro-inflammatory cytokines IL-8, TNF-α, and IL-6 in nasopharyngeal samples were reduced by 1.1, 3.7, and 53.9 folds, respectively. Compared to the standard control group, treatment regimen with LiveSpo Navax demonstrated significantly greater effectiveness, resulting in 26-fold reduction in viral load, 65-fold reduction in bacterial concentration, and 1.1-9.5-fold decrease in cytokine levels. Overall, nasal-spraying Bacillus spores can support the symptomatic treatment of influenza virus-induced ARTIs quickly, efficiently and could be used as a cost-effective supportive treatment for respiratory viral infection in general.Clinical trial registration no: NCT05378022 on 17/05/2022.